Product Reports Resources Pricing Login Book a demo

MacroGenics

Biotech & Life Sciences · Rockville, United States · Founded 2000 · IPO 2013

Developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases

Valuation $117M
Revenue $164M

Investors

13 investors on MacroGenics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Alexandria Equities
InterWest Partners
Startech Early Ventures
OrbiMed
MPM BioImpact
Series B+ 8 investors entered at this stage
Rockefeller University
Institute for Systems Biology
Mithra Ventures
TPG
Ventures West
Alta Partners
Red Abbey Venture Partners
ETP Ventures

Global footprint

Where MacroGenics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.6%
🇦🇷 Argentina0.4%
2 countries shown
Web traffic by country
8.6K monthly visits
across markets
🇺🇸 United States70.9%
🇮🇳 India15.1%
🇯🇵 Japan7%
🇬🇧 United Kingdom4.7%
🇨🇦 Canada2.3%
Top 5 markets shown

Talent graph

The shape of MacroGenics's talent

Dealroom maps MacroGenics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock MacroGenics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$134M patent portfolio · 69 active families

Estimated portfolio value
$134M
114.9% of market cap · 3.6× smaller than top peer Genmab ($488M)
69 active patent families
Where MacroGenics innovates Antiendomysial antibodiesAntigenBiochemistryCancer researchCarcinosis

Where MacroGenics concentrates vs peers

Each axis is a top-10 topic across MacroGenics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about MacroGenics

An AI-synthesized read of the highest-engagement posts about MacroGenics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MacroGenics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.